Menu
Not yet recruiting NCT06543264

Efficacy of Cryotherapy in Managing Chemotherapy-Induced Peripheral Neuropathy in Children With Leukemia

No phase Interventional Cancer

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Cryotherapy.
Who it may be relevant to
Registry conditions: Cancer. Basic parameters: 8 years — 17 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
Egypt
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Overview

This study aimed to assess the efficacy of cryotherapy in controlling Peripheral Neuropathy in cancer children

Detailed description

Peripheral neuropathy is a serious condition characterized by symmetrical, distal damage to the peripheral nerves that may be caused by several classes of drugs, including chemotherapeutic agents. Chemotherapy-induced peripheral neuropathy (CIPN) is an adverse effect estimated to occur in up to 40% of patients undergoing chemotherapy, with its incidence increasing in patients being treated with multiple agents. Pharmacists play a pivotal role in the prevention and management of CIPN by recommending evidence-based pharmacologic and non pharmacologic strategies appropriate for the individual patient.Peripheral neuropathy (PN) is a systemic disease characterized by symmetrical, distal damage to the peripheral nerves that negatively impacts patient quality of life (QOL). Prolonged symptoms associated with PN can cause pain, interfere with functional ability (e.g., dressing, driving, house-work), and disrupt emotional health.

Interventions

  • Device Cryotherapy
    Cryotherapy is a pain treatment that uses a method of localized freezing temperatures to deaden an irritated nerve. Cryotherapy is also used as a method of treating localized areas of some cancers (called cryosurgery), such as prostate cancer and to treat abnormal skin cells by dermatologists

Primary outcome measures

  • Nerve conduction studies (NCS) [Time frame: nerve conduction velocity for sensory ulnar nerve at day 0]
  • Nerve conduction studies (NCS) [Time frame: nerve conduction velocity for sensory ulnar nerve at day 90]
  • Nerve conduction studies (NCS) [Time frame: nerve conduction velocity for sensory sensory median nerve at day 0]
  • Nerve conduction studies (NCS) [Time frame: nerve conduction velocity for sensory sensory median nerve at day 90]

Eligibility criteria

Inclusion criteria

  • Their age will ranging from eight to seventeen years.
  • Children participated in this study will from both sexes.
  • Children receiving chemotherapy as medical treatment protocol
  • All children have polyneuropathy caused by chemotherapy.

Exclusion criteria

  • Children with Epilepsy.
  • Children with blood clotting disorder.
  • Children have Open wounds / broken skin
  • Children with severe cardiac disease
  • Uncooperative patients.

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
Randomized
Model
Parallel assignment
Masking
Double blind
Primary purpose
Treatment

Study locations

Egypt · 1 center
  • South Valley University, Faculty of Physical Therapy — Qina

Identifiers

NCT: NCT06543264 · Cryotherapy and Leukemia

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗